Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

Inclusion criteria

• Subjects with Normal Hepatic Function:

• Weighs at least 45 kg
• Body mass index between 18 and 40 kg/m2 inclusive
• Must have normal hepatic function
• Hepatic Impaired Subjects:

• Weighs at least 45 kg
• Meets criteria for mild or moderate hepatic impairment defined by Child-Pugh method
• Body mass index between 18 and 40 kg/m2 inclusive

Exclusion criteria

• Subjects with Normal Hepatic Function:

• Smokes more than 10 cigarettes per day
• Known to be HIV positive or has HIV antibodies
• Has clinically significant history or presence of illness, malignancy, or immunodeficiency
• Is Hepatitis A, B, or C positive
• Has had a blood transfusion or donated/lost more than 550ml of blood within 8 weeks of study drug administration
• History of substance abuse within 6 months prior to screening
• Hepatic Impaired Subjects:

• Has history or presence of biliary obstruction or biliary disease, hepatic encephalopathy, advanced acidities, portal hypertension, or biliary liver cirrhosis
• Is hypovolemic or has evidence of orthostatic hypotension
• Smokes more than 10 cigarettes per day
• Known to be HIV positive or has HIV antibodies
• Has clinically significant history or presence of illness, malignancy, or immunodeficiency
• Has clinically significant history or presence of GI symptoms other than those associated with moderate hepatic impairment
• Has had a blood transfusion or donated/lost more than 550ml of blood within 8 weeks of study drug administration
• History of substance abuse within 6 months prior to screening